Rosmarinus officinallis improves learning and memory of mouse model of Morris water maze
DOI:
https://doi.org/10.31157/an.v22i2.149Keywords:
rosemary oil, Morris water maze, memory, learning.Abstract
Rosmarinus officinalis known as rosemary oil is used in herbal medicine, recent studies have found that some alkaloids act as antidepressants and anti-inflammatories because of their inhibitory activity on acetylcholinesterase and butyrylcholinesterase, so that rosemary could be a complementary treatment for the disease. Alzheimer's disease, because this disease is linked to an acetylcholine deficiency. Objective: to evaluate the effect of rosemary oil on learning through the Morris water maze. Material: twenty-four male CD1 mice weighing 20-30g were divided into four groups: 1. saline solution intraperitoneally 2. memantine (10μg/kg) intraperitoneally, 3. rosemary oil (20μg/kg) inhalation and 4.rosemary oil (120μg/Kg) oral administration. The time that remained in each quadrant was measured as a way of evaluating learning, through the recognition of the area. Results: It was found that the group treated with oral rosemary oil had a learning similar to that of memantine, a drug used to treat Alzheimer's, in which the group treated by inhalation was not significant. Conclusions: The present study showed that mice treated with oral rosemary oil did exhibit a tendency to improve performance in the Morris water maze compared to mice treated by inhalation, indicating that improved learning and memory capacity, is the beginning for complementary treatments in Alzheimer's disease and other types of dementia using rosemary oil.Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2017 Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez
This work is licensed under a Creative Commons Attribution 4.0 International License.
September 2022-present © Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez. Open access articles under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) license, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. No commercial re-use is allowed.
January-September 2022 © The authors. Open access articles under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) license, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. No commercial re-use is allowed.
January 2014-December 2021 © Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez. Open access articles under the terms of the Creative Commons Attribution 4.0 International (CC BY 4.0) license, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.